AU2004299718A1 - Stem cells - Google Patents
Stem cells Download PDFInfo
- Publication number
- AU2004299718A1 AU2004299718A1 AU2004299718A AU2004299718A AU2004299718A1 AU 2004299718 A1 AU2004299718 A1 AU 2004299718A1 AU 2004299718 A AU2004299718 A AU 2004299718A AU 2004299718 A AU2004299718 A AU 2004299718A AU 2004299718 A1 AU2004299718 A1 AU 2004299718A1
- Authority
- AU
- Australia
- Prior art keywords
- cells
- cell population
- stem
- stem cell
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 210000000130 stem cell Anatomy 0.000 title claims description 153
- 210000004027 cell Anatomy 0.000 claims description 313
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 77
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 77
- 238000000034 method Methods 0.000 claims description 52
- 210000001519 tissue Anatomy 0.000 claims description 41
- 230000001464 adherent effect Effects 0.000 claims description 34
- 230000004069 differentiation Effects 0.000 claims description 33
- 239000004033 plastic Substances 0.000 claims description 33
- 229920003023 plastic Polymers 0.000 claims description 33
- 108090000623 proteins and genes Proteins 0.000 claims description 30
- 210000001185 bone marrow Anatomy 0.000 claims description 28
- 210000004185 liver Anatomy 0.000 claims description 26
- 230000003394 haemopoietic effect Effects 0.000 claims description 24
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 20
- 239000011324 bead Substances 0.000 claims description 18
- 238000011069 regeneration method Methods 0.000 claims description 17
- 239000008280 blood Substances 0.000 claims description 16
- 239000003446 ligand Substances 0.000 claims description 16
- 210000004369 blood Anatomy 0.000 claims description 15
- 230000000694 effects Effects 0.000 claims description 15
- 102000004169 proteins and genes Human genes 0.000 claims description 15
- 238000012258 culturing Methods 0.000 claims description 14
- 238000004519 manufacturing process Methods 0.000 claims description 14
- 230000008929 regeneration Effects 0.000 claims description 14
- 238000000926 separation method Methods 0.000 claims description 13
- 239000003550 marker Substances 0.000 claims description 11
- 101000610551 Homo sapiens Prominin-1 Proteins 0.000 claims description 10
- 102000004877 Insulin Human genes 0.000 claims description 10
- 108090001061 Insulin Proteins 0.000 claims description 10
- 241001465754 Metazoa Species 0.000 claims description 10
- 229940125396 insulin Drugs 0.000 claims description 10
- 230000001605 fetal effect Effects 0.000 claims description 9
- 230000012010 growth Effects 0.000 claims description 9
- 210000000056 organ Anatomy 0.000 claims description 9
- 230000001225 therapeutic effect Effects 0.000 claims description 9
- 108010088751 Albumins Proteins 0.000 claims description 8
- 102000009088 Angiopoietin-1 Human genes 0.000 claims description 8
- 108010048154 Angiopoietin-1 Proteins 0.000 claims description 8
- 241000282414 Homo sapiens Species 0.000 claims description 8
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 8
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 8
- 239000003102 growth factor Substances 0.000 claims description 8
- 238000000338 in vitro Methods 0.000 claims description 8
- 102100033421 Keratin, type I cytoskeletal 18 Human genes 0.000 claims description 7
- 108010066327 Keratin-18 Proteins 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 239000011521 glass Substances 0.000 claims description 7
- 239000007787 solid Substances 0.000 claims description 7
- 239000013598 vector Substances 0.000 claims description 7
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims description 6
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims description 6
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims description 6
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims description 6
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 6
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 claims description 6
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 6
- 102100034434 Nebulin Human genes 0.000 claims description 6
- 102100040120 Prominin-1 Human genes 0.000 claims description 6
- 210000004504 adult stem cell Anatomy 0.000 claims description 6
- 210000000988 bone and bone Anatomy 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 238000002955 isolation Methods 0.000 claims description 6
- 108010054130 nebulin Proteins 0.000 claims description 6
- 101100481408 Danio rerio tie2 gene Proteins 0.000 claims description 5
- 102000006354 HLA-DR Antigens Human genes 0.000 claims description 5
- 108010058597 HLA-DR Antigens Proteins 0.000 claims description 5
- 101000603702 Homo sapiens Neurogenin-3 Proteins 0.000 claims description 5
- 101100481410 Mus musculus Tek gene Proteins 0.000 claims description 5
- 102100038553 Neurogenin-3 Human genes 0.000 claims description 5
- 238000005138 cryopreservation Methods 0.000 claims description 5
- 230000005298 paramagnetic effect Effects 0.000 claims description 5
- XQTLDIFVVHJORV-UHFFFAOYSA-N tecnazene Chemical compound [O-][N+](=O)C1=C(Cl)C(Cl)=CC(Cl)=C1Cl XQTLDIFVVHJORV-UHFFFAOYSA-N 0.000 claims description 5
- 238000002560 therapeutic procedure Methods 0.000 claims description 5
- 238000002054 transplantation Methods 0.000 claims description 5
- 102000009075 Angiopoietin-2 Human genes 0.000 claims description 4
- 108010048036 Angiopoietin-2 Proteins 0.000 claims description 4
- 101150044441 PECAM1 gene Proteins 0.000 claims description 4
- 102000004903 Troponin Human genes 0.000 claims description 4
- 108090001027 Troponin Proteins 0.000 claims description 4
- 108010065472 Vimentin Proteins 0.000 claims description 4
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 claims description 4
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 claims description 4
- 229940024142 alpha 1-antitrypsin Drugs 0.000 claims description 4
- 108010026331 alpha-Fetoproteins Proteins 0.000 claims description 4
- 230000001537 neural effect Effects 0.000 claims description 4
- 210000000496 pancreas Anatomy 0.000 claims description 4
- 230000001172 regenerating effect Effects 0.000 claims description 4
- 230000008093 supporting effect Effects 0.000 claims description 4
- 239000003053 toxin Substances 0.000 claims description 4
- 231100000765 toxin Toxicity 0.000 claims description 4
- 210000005048 vimentin Anatomy 0.000 claims description 4
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 3
- 102000001045 Connexin 43 Human genes 0.000 claims description 3
- 108010069241 Connexin 43 Proteins 0.000 claims description 3
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 3
- 102100037872 Intercellular adhesion molecule 2 Human genes 0.000 claims description 3
- 101710148794 Intercellular adhesion molecule 2 Proteins 0.000 claims description 3
- 210000000845 cartilage Anatomy 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 231100000419 toxicity Toxicity 0.000 claims description 3
- 230000001988 toxicity Effects 0.000 claims description 3
- 210000003954 umbilical cord Anatomy 0.000 claims description 3
- 241000283690 Bos taurus Species 0.000 claims description 2
- 102000000905 Cadherin Human genes 0.000 claims description 2
- 108050007957 Cadherin Proteins 0.000 claims description 2
- 102100036912 Desmin Human genes 0.000 claims description 2
- 108010044052 Desmin Proteins 0.000 claims description 2
- 101001051093 Homo sapiens Low-density lipoprotein receptor Proteins 0.000 claims description 2
- 101000851357 Homo sapiens Troponin T, slow skeletal muscle Proteins 0.000 claims description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 2
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 claims description 2
- 101100013973 Mus musculus Gata4 gene Proteins 0.000 claims description 2
- 101100452019 Mus musculus Icam2 gene Proteins 0.000 claims description 2
- 102000008730 Nestin Human genes 0.000 claims description 2
- 108010088225 Nestin Proteins 0.000 claims description 2
- 102000007354 PAX6 Transcription Factor Human genes 0.000 claims description 2
- 108010032788 PAX6 Transcription Factor Proteins 0.000 claims description 2
- -1 Pdx=l Proteins 0.000 claims description 2
- 102000004338 Transferrin Human genes 0.000 claims description 2
- 108090000901 Transferrin Proteins 0.000 claims description 2
- 102100036860 Troponin T, slow skeletal muscle Human genes 0.000 claims description 2
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 claims description 2
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims description 2
- 210000004556 brain Anatomy 0.000 claims description 2
- 210000005045 desmin Anatomy 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 210000003205 muscle Anatomy 0.000 claims description 2
- 210000005055 nestin Anatomy 0.000 claims description 2
- 230000035755 proliferation Effects 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 239000012581 transferrin Substances 0.000 claims description 2
- 230000014616 translation Effects 0.000 claims description 2
- 239000002753 trypsin inhibitor Substances 0.000 claims description 2
- 125000000962 organic group Chemical group 0.000 claims 4
- 108020004414 DNA Proteins 0.000 claims 2
- 101100480530 Danio rerio tal1 gene Proteins 0.000 claims 2
- 101100480538 Mus musculus Tal1 gene Proteins 0.000 claims 2
- 101100312945 Pasteurella multocida (strain Pm70) talA gene Proteins 0.000 claims 2
- 101150045640 VWF gene Proteins 0.000 claims 2
- 238000003780 insertion Methods 0.000 claims 2
- 230000037431 insertion Effects 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 102000009027 Albumins Human genes 0.000 claims 1
- 101710081722 Antitrypsin Proteins 0.000 claims 1
- 102000053642 Catalytic RNA Human genes 0.000 claims 1
- 108090000994 Catalytic RNA Proteins 0.000 claims 1
- 241000283073 Equus caballus Species 0.000 claims 1
- 102100023374 Forkhead box protein M1 Human genes 0.000 claims 1
- 102100021866 Hepatocyte growth factor Human genes 0.000 claims 1
- 101000907578 Homo sapiens Forkhead box protein M1 Proteins 0.000 claims 1
- 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 claims 1
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 claims 1
- 101000868152 Homo sapiens Son of sevenless homolog 1 Proteins 0.000 claims 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims 1
- 241001529936 Murinae Species 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 101710150336 Protein Rex Proteins 0.000 claims 1
- 102000013127 Vimentin Human genes 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 102000013529 alpha-Fetoproteins Human genes 0.000 claims 1
- 230000000692 anti-sense effect Effects 0.000 claims 1
- 230000001475 anti-trypsic effect Effects 0.000 claims 1
- 230000009286 beneficial effect Effects 0.000 claims 1
- 241001493065 dsRNA viruses Species 0.000 claims 1
- 210000000987 immune system Anatomy 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000001177 retroviral effect Effects 0.000 claims 1
- 108091092562 ribozyme Proteins 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 description 19
- 108090000695 Cytokines Proteins 0.000 description 19
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 15
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 15
- 238000011534 incubation Methods 0.000 description 15
- 210000004524 haematopoietic cell Anatomy 0.000 description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 12
- 230000014509 gene expression Effects 0.000 description 12
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 10
- 102100027211 Albumin Human genes 0.000 description 8
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 8
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 8
- 101800003838 Epidermal growth factor Proteins 0.000 description 7
- 102100033237 Pro-epidermal growth factor Human genes 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 229940116977 epidermal growth factor Drugs 0.000 description 7
- 238000003365 immunocytochemistry Methods 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 210000005259 peripheral blood Anatomy 0.000 description 7
- 239000011886 peripheral blood Substances 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 210000002536 stromal cell Anatomy 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 6
- 101710088580 Stromal cell-derived factor 1 Proteins 0.000 description 6
- 108010017842 Telomerase Proteins 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 210000004700 fetal blood Anatomy 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 210000005036 nerve Anatomy 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 230000035899 viability Effects 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 239000012981 Hank's balanced salt solution Substances 0.000 description 5
- 102100039064 Interleukin-3 Human genes 0.000 description 5
- 108010002386 Interleukin-3 Proteins 0.000 description 5
- 101150052863 THY1 gene Proteins 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 238000000684 flow cytometry Methods 0.000 description 5
- 210000003494 hepatocyte Anatomy 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 229940076264 interleukin-3 Drugs 0.000 description 5
- 210000005229 liver cell Anatomy 0.000 description 5
- 210000005087 mononuclear cell Anatomy 0.000 description 5
- 230000002035 prolonged effect Effects 0.000 description 5
- 206010000830 Acute leukaemia Diseases 0.000 description 4
- 102100023635 Alpha-fetoprotein Human genes 0.000 description 4
- 102100022623 Hepatocyte growth factor receptor Human genes 0.000 description 4
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 4
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 108010062276 T-Cell Acute Lymphocytic Leukemia Protein 1 Proteins 0.000 description 4
- 102000011768 T-Cell Acute Lymphocytic Leukemia Protein 1 Human genes 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 208000035896 Twin-reversed arterial perfusion sequence Diseases 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000001332 colony forming effect Effects 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 239000006166 lysate Substances 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 229920000609 methyl cellulose Polymers 0.000 description 4
- 239000001923 methylcellulose Substances 0.000 description 4
- 235000010981 methylcellulose Nutrition 0.000 description 4
- 229960003966 nicotinamide Drugs 0.000 description 4
- 235000005152 nicotinamide Nutrition 0.000 description 4
- 239000011570 nicotinamide Substances 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 210000002027 skeletal muscle Anatomy 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 108010085238 Actins Proteins 0.000 description 3
- 102000007469 Actins Human genes 0.000 description 3
- 229920002157 Cellulin Polymers 0.000 description 3
- 102000009410 Chemokine receptor Human genes 0.000 description 3
- 108050000299 Chemokine receptor Proteins 0.000 description 3
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 3
- 102100021238 Dynamin-2 Human genes 0.000 description 3
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 3
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 3
- 102100028072 Fibroblast growth factor 4 Human genes 0.000 description 3
- 108091008603 HGF receptors Proteins 0.000 description 3
- 101000817607 Homo sapiens Dynamin-2 Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 102100041030 Pancreas/duodenum homeobox protein 1 Human genes 0.000 description 3
- 101710144033 Pancreas/duodenum homeobox protein 1 Proteins 0.000 description 3
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 3
- 101710204736 Platelet endothelial cell adhesion molecule Proteins 0.000 description 3
- 102100035071 Vimentin Human genes 0.000 description 3
- 108010023082 activin A Proteins 0.000 description 3
- 230000000735 allogeneic effect Effects 0.000 description 3
- 239000002870 angiogenesis inducing agent Substances 0.000 description 3
- 210000001130 astrocyte Anatomy 0.000 description 3
- 230000022131 cell cycle Effects 0.000 description 3
- 239000002771 cell marker Substances 0.000 description 3
- 238000005345 coagulation Methods 0.000 description 3
- 230000015271 coagulation Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000003306 harvesting Methods 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 230000005291 magnetic effect Effects 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- 210000004940 nucleus Anatomy 0.000 description 3
- 238000011580 nude mouse model Methods 0.000 description 3
- 210000002460 smooth muscle Anatomy 0.000 description 3
- YEENEYXBHNNNGV-XEHWZWQGSA-M sodium;3-acetamido-5-[acetyl(methyl)amino]-2,4,6-triiodobenzoate;(2r,3r,4s,5s,6r)-2-[(2r,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound [Na+].CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I.O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 YEENEYXBHNNNGV-XEHWZWQGSA-M 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 2
- 229930105110 Cyclosporin A Natural products 0.000 description 2
- 108010036949 Cyclosporine Proteins 0.000 description 2
- 241000702421 Dependoparvovirus Species 0.000 description 2
- 206010015866 Extravasation Diseases 0.000 description 2
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 description 2
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102000009094 Hepatocyte Nuclear Factor 3-beta Human genes 0.000 description 2
- 108010087745 Hepatocyte Nuclear Factor 3-beta Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101001060274 Homo sapiens Fibroblast growth factor 4 Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 101100519293 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pdx-1 gene Proteins 0.000 description 2
- 102000012753 TIE-2 Receptor Human genes 0.000 description 2
- 108010090091 TIE-2 Receptor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 2
- 210000004413 cardiac myocyte Anatomy 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229960001265 ciclosporin Drugs 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 238000011018 current good manufacturing practice Methods 0.000 description 2
- 229930182912 cyclosporin Natural products 0.000 description 2
- 231100000599 cytotoxic agent Toxicity 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 210000003981 ectoderm Anatomy 0.000 description 2
- 210000001900 endoderm Anatomy 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 210000003038 endothelium Anatomy 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000036251 extravasation Effects 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 210000003716 mesoderm Anatomy 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000000663 muscle cell Anatomy 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 230000004481 post-translational protein modification Effects 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 210000002235 sarcomere Anatomy 0.000 description 2
- 238000007790 scraping Methods 0.000 description 2
- 210000002363 skeletal muscle cell Anatomy 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 238000012384 transportation and delivery Methods 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 1
- 101150110188 30 gene Proteins 0.000 description 1
- 101150096316 5 gene Proteins 0.000 description 1
- NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 description 1
- 108010049974 Bone Morphogenetic Protein 6 Proteins 0.000 description 1
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 description 1
- 102100022525 Bone morphogenetic protein 6 Human genes 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- 235000009025 Carya illinoensis Nutrition 0.000 description 1
- 241001453450 Carya illinoinensis Species 0.000 description 1
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
- 108090000381 Fibroblast growth factor 4 Proteins 0.000 description 1
- 108090000368 Fibroblast growth factor 8 Proteins 0.000 description 1
- 102100037680 Fibroblast growth factor 8 Human genes 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 102000009331 Homeodomain Proteins Human genes 0.000 description 1
- 108010048671 Homeodomain Proteins Proteins 0.000 description 1
- 101000998020 Homo sapiens Keratin, type I cytoskeletal 18 Proteins 0.000 description 1
- 101000994460 Homo sapiens Keratin, type I cytoskeletal 20 Proteins 0.000 description 1
- 101000931371 Homo sapiens Zinc finger protein ZFPM2 Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 102000012411 Intermediate Filament Proteins Human genes 0.000 description 1
- 108010061998 Intermediate Filament Proteins Proteins 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 101710096141 Neurogenin-3 Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 108010089836 Proto-Oncogene Proteins c-met Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 208000002903 Thalassemia Diseases 0.000 description 1
- 102000002689 Toll-like receptor Human genes 0.000 description 1
- 108020000411 Toll-like receptor Proteins 0.000 description 1
- 108010048992 Transcription Factor 4 Proteins 0.000 description 1
- 102100023489 Transcription factor 4 Human genes 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102100020996 Zinc finger protein ZFPM2 Human genes 0.000 description 1
- 108091007916 Zinc finger transcription factors Proteins 0.000 description 1
- 102000038627 Zinc finger transcription factors Human genes 0.000 description 1
- CJGYSWNGNKCJSB-YVLZZHOMSA-M [(4ar,6r,7r,7ar)-6-[6-(butanoylamino)purin-9-yl]-2-oxido-2-oxo-4a,6,7,7a-tetrahydro-4h-furo[3,2-d][1,3,2]dioxaphosphinin-7-yl] butanoate Chemical compound C([C@H]1O2)OP([O-])(=O)O[C@H]1[C@@H](OC(=O)CCC)[C@@H]2N1C(N=CN=C2NC(=O)CCC)=C2N=C1 CJGYSWNGNKCJSB-YVLZZHOMSA-M 0.000 description 1
- 108010076089 accutase Proteins 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 210000002867 adherens junction Anatomy 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 238000003314 affinity selection Methods 0.000 description 1
- 206010001584 alcohol abuse Diseases 0.000 description 1
- 208000025746 alcohol use disease Diseases 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 238000002617 apheresis Methods 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000003969 blast cell Anatomy 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000031154 cholesterol homeostasis Effects 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000000093 cytochemical effect Effects 0.000 description 1
- 102000003675 cytokine receptors Human genes 0.000 description 1
- 108010057085 cytokine receptors Proteins 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000003436 cytoskeletal effect Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000024531 detection of redox state Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000003237 epithelioid cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000000267 erythroid cell Anatomy 0.000 description 1
- 230000000925 erythroid effect Effects 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 231100000722 genetic damage Toxicity 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 238000011773 genetically engineered mouse model Methods 0.000 description 1
- 210000001654 germ layer Anatomy 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000008629 immune suppression Effects 0.000 description 1
- 238000013394 immunophenotyping Methods 0.000 description 1
- 239000002596 immunotoxin Substances 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002506 iron compounds Chemical class 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000007798 limiting dilution analysis Methods 0.000 description 1
- 230000004132 lipogenesis Effects 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000007885 magnetic separation Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 229940031182 nanoparticles iron oxide Drugs 0.000 description 1
- 210000003061 neural cell Anatomy 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000005868 ontogenesis Effects 0.000 description 1
- 230000021368 organ growth Effects 0.000 description 1
- 230000033667 organ regeneration Effects 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 238000004091 panning Methods 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 210000004738 parenchymal cell Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000012207 quantitative assay Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000023895 stem cell maintenance Effects 0.000 description 1
- 238000011476 stem cell transplantation Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 210000000352 storage cell Anatomy 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- YUKQRDCYNOVPGJ-UHFFFAOYSA-N thioacetamide Chemical compound CC(N)=S YUKQRDCYNOVPGJ-UHFFFAOYSA-N 0.000 description 1
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0607—Non-embryonic pluripotent stem cells, e.g. MASC
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/70—Polysaccharides
- C12N2533/78—Cellulose
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Gynecology & Obstetrics (AREA)
- Neurology (AREA)
- Reproductive Health (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0329449.3A GB0329449D0 (en) | 2003-12-19 | 2003-12-19 | Stem cells |
| GB0329449.3 | 2003-12-19 | ||
| PCT/GB2004/005365 WO2005059113A1 (en) | 2003-12-19 | 2004-12-20 | Stem cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2004299718A1 true AU2004299718A1 (en) | 2005-06-30 |
Family
ID=30776110
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2004299718A Abandoned AU2004299718A1 (en) | 2003-12-19 | 2004-12-20 | Stem cells |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20070274970A1 (https=) |
| EP (1) | EP1697500B1 (https=) |
| JP (2) | JP2007514434A (https=) |
| KR (1) | KR20070004574A (https=) |
| CN (1) | CN1918284B (https=) |
| AU (1) | AU2004299718A1 (https=) |
| BR (1) | BRPI0417194A (https=) |
| CA (1) | CA2549930C (https=) |
| EA (1) | EA200601187A1 (https=) |
| GB (1) | GB0329449D0 (https=) |
| MX (1) | MXPA06006706A (https=) |
| WO (1) | WO2005059113A1 (https=) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1786471B1 (en) | 2004-07-30 | 2015-02-11 | Mayo Foundation For Medical Education And Research | Treating cardiovascular tissue |
| EP1791952A4 (en) * | 2004-08-13 | 2008-06-11 | Univ Georgia Res Found | COMPOSITIONS AND METHODS OF SELF-RENEWAL AND DIFFERENTIATION IN HUMAN EMBRYONAL STEM CELLS |
| GB0509500D0 (en) * | 2005-05-10 | 2005-06-15 | Revealcyte | Method of fetal cell enrichment |
| WO2008003042A2 (en) * | 2006-06-28 | 2008-01-03 | The University Of Medicine And Dentistry Of New Jersey | Amnion-derived stem cells and uses thereof |
| US9765298B2 (en) | 2006-07-24 | 2017-09-19 | Mayo Foundation For Medical Education And Research | Methods and materials for providing cardiac cells |
| US8739148B2 (en) * | 2007-02-09 | 2014-05-27 | Elster Electricity, Llc | Automated meter reading system |
| WO2009011139A1 (ja) * | 2007-07-13 | 2009-01-22 | Mitsubishi Tanabe Pharma Corporation | 細胞の単離方法、細胞用無血清培養培地および細胞の培養方法 |
| ES2325715B1 (es) * | 2007-08-03 | 2010-06-17 | Genetrix, S.L. | Poblacion de celulas madre adultas derivadas de tejido adiposo cardiaco y su uso en regeneracion cardiaca. |
| JP2009278873A (ja) * | 2008-05-19 | 2009-12-03 | Japan Health Science Foundation | 培地および培養方法 |
| WO2009145761A1 (en) * | 2008-05-27 | 2009-12-03 | Mayo Foundation For Medical Education And Research | Methods and materials for using cells to treat heart tissue |
| CN101314767A (zh) * | 2008-07-03 | 2008-12-03 | 上海天生生物科技有限公司 | 增强胎肝造血干细胞cd34表达的培养液及其制备方法 |
| GB0818725D0 (en) * | 2008-10-13 | 2008-11-19 | Habib Nagy A | Pharmaceutical composition |
| WO2010056341A2 (en) * | 2008-11-12 | 2010-05-20 | The University Of Vermont And State Agriculture College | Compositions and methods for tissue repair |
| WO2010062999A1 (en) * | 2008-11-28 | 2010-06-03 | Stematix, Inc | Diabetes cell therapy |
| CN102803472B (zh) * | 2009-06-25 | 2014-04-23 | 吉隆公司 | 去除了外来表型的由多能干细胞分化的子代细胞 |
| JPWO2011102532A1 (ja) * | 2010-02-16 | 2013-06-17 | 国立大学法人九州大学 | 誘導肝細胞 |
| US8731261B2 (en) | 2010-02-23 | 2014-05-20 | Loma Linda University | Method of analyzing a medical image |
| WO2012046065A2 (en) | 2010-10-06 | 2012-04-12 | Omnicyte Limited | Culture method |
| EP2625264B1 (en) | 2010-10-08 | 2022-12-07 | Terumo BCT, Inc. | Methods and systems of growing and harvesting cells in a hollow fiber bioreactor system with control conditions |
| KR20130132795A (ko) | 2010-10-08 | 2013-12-05 | 미나 테라퓨틱스 리미티드 | 짧은 rna 분자 |
| EP4060043A1 (en) | 2011-06-21 | 2022-09-21 | MiNA Therapeutics Limited | Albumin production and cell proliferation |
| US20160127672A1 (en) | 2013-02-28 | 2016-05-05 | Nikon Corporation | Electronic apparatus |
| JP6633522B2 (ja) | 2013-11-16 | 2020-01-22 | テルモ ビーシーティー、インコーポレーテッド | バイオリアクターにおける細胞増殖 |
| WO2015148704A1 (en) | 2014-03-25 | 2015-10-01 | Terumo Bct, Inc. | Passive replacement of media |
| US20160090569A1 (en) | 2014-09-26 | 2016-03-31 | Terumo Bct, Inc. | Scheduled Feed |
| US10350245B2 (en) * | 2015-01-21 | 2019-07-16 | Fred Hutchinson Cancer Research Center | Point-of-care and/or portable platform for gene therapy |
| WO2017004592A1 (en) | 2015-07-02 | 2017-01-05 | Terumo Bct, Inc. | Cell growth with mechanical stimuli |
| JP7034949B2 (ja) | 2016-05-25 | 2022-03-14 | テルモ ビーシーティー、インコーポレーテッド | 細胞の増殖 |
| US11685883B2 (en) | 2016-06-07 | 2023-06-27 | Terumo Bct, Inc. | Methods and systems for coating a cell growth surface |
| US11104874B2 (en) | 2016-06-07 | 2021-08-31 | Terumo Bct, Inc. | Coating a bioreactor |
| US11624046B2 (en) | 2017-03-31 | 2023-04-11 | Terumo Bct, Inc. | Cell expansion |
| US12234441B2 (en) | 2017-03-31 | 2025-02-25 | Terumo Bct, Inc. | Cell expansion |
| CN117247899A (zh) | 2017-03-31 | 2023-12-19 | 泰尔茂比司特公司 | 细胞扩增 |
| MX2022011245A (es) | 2020-03-11 | 2023-01-11 | Bit Bio Ltd | Método de generación de células hepáticas. |
| GB2619893A (en) | 2021-03-23 | 2023-12-20 | Terumo Bct Inc | Cell capture and expansion |
| US12152699B2 (en) | 2022-02-28 | 2024-11-26 | Terumo Bct, Inc. | Multiple-tube pinch valve assembly |
| USD1099116S1 (en) | 2022-09-01 | 2025-10-21 | Terumo Bct, Inc. | Display screen or portion thereof with a graphical user interface for displaying cell culture process steps and measurements of an associated bioreactor device |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06510672A (ja) * | 1991-11-05 | 1994-12-01 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | サプレッサーおよび前駆細胞 |
| JPH08506007A (ja) * | 1992-11-16 | 1996-07-02 | アプライド イミューン サイエンシーズ，インコーポレイテッド | 多能性の休止状態の幹細胞集団 |
| ES2252932T3 (es) * | 1998-02-05 | 2006-05-16 | Novartis Ag | Poblaciones expandidas y geneticamente modificadas de celulas madre hematopoyeticas humanas. |
| US7838289B2 (en) * | 2001-02-14 | 2010-11-23 | Abt Holding Company | Assay utilizing multipotent adult stem cells |
| WO2001015521A1 (en) * | 1999-08-31 | 2001-03-08 | Genencor International, Inc. | Transgenic mammal capable of facilitating production of donor-specific functional immunity |
| AU2001250966A1 (en) * | 2000-03-23 | 2001-10-03 | Stem Cells, Inc. | Pluripotential stem cells |
| CA2412436C (en) * | 2000-06-05 | 2013-05-21 | The Trustees Of Columbia University In The City Of New York | Identification and use of human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury |
| US6930222B2 (en) * | 2000-08-22 | 2005-08-16 | The Scripps Research Institute | In vivo animal model of human leukemia |
| US7560280B2 (en) * | 2000-11-03 | 2009-07-14 | Kourion Therapeutics Gmbh | Human cord blood derived unrestricted somatic stem cells (USSC) |
| EP1385935A4 (en) * | 2001-03-29 | 2004-09-15 | Ixion Biotechnology Inc | METHOD FOR TRANSDIFFERENTIATION OF NON-PANCREATIC STEM CELLS IN THE PANCREAS DIFFERENTIATION PATHWAY |
| EP1423012B1 (en) * | 2001-08-10 | 2007-11-14 | Imclone Systems, Inc. | Medical use of stem cells expressing vegfr-1 |
| EP1458854B1 (en) * | 2001-12-21 | 2010-04-14 | Mount Sinai Hospital | Cellular compositions and methods of making and using them |
| US20040009589A1 (en) * | 2002-03-26 | 2004-01-15 | Shulamit Levenberg | Endothelial cells derived from human embryonic stem cells |
| AU2003221173A1 (en) * | 2002-03-27 | 2003-10-08 | Asahi Kasei Kabushiki Kaisha | Placenta-origin mesenchymal cells and medicinal use thereof |
| WO2004087896A2 (en) * | 2003-03-31 | 2004-10-14 | Pfizer Products Inc. | Hepatocyte differentiation of stem cells |
| WO2006060779A2 (en) * | 2004-12-03 | 2006-06-08 | Case Western Reserve University | Novel methods, compositions and devices for inducing neovascularization |
| WO2007149548A2 (en) * | 2006-06-22 | 2007-12-27 | Medistem Laboratories, Inc. | Treatment of erectile dysfunction by stem cell therapy |
| WO2008024996A2 (en) * | 2006-08-24 | 2008-02-28 | Johnstone Brian H | Production of neural protective and regenerative factors from stem cells and treatment of nervous system conditions therewith |
| EP2076116A4 (en) * | 2006-10-11 | 2010-04-07 | Gen Hospital Corp | COMPOSITIONS, METHODS, AND DEVICES FOR TREATING HEPATIC DISEASES |
-
2003
- 2003-12-19 GB GBGB0329449.3A patent/GB0329449D0/en not_active Ceased
-
2004
- 2004-12-20 EP EP04806164A patent/EP1697500B1/en not_active Expired - Lifetime
- 2004-12-20 US US10/583,188 patent/US20070274970A1/en not_active Abandoned
- 2004-12-20 MX MXPA06006706A patent/MXPA06006706A/es active IP Right Grant
- 2004-12-20 AU AU2004299718A patent/AU2004299718A1/en not_active Abandoned
- 2004-12-20 KR KR1020067014238A patent/KR20070004574A/ko not_active Ceased
- 2004-12-20 WO PCT/GB2004/005365 patent/WO2005059113A1/en not_active Ceased
- 2004-12-20 JP JP2006544560A patent/JP2007514434A/ja active Pending
- 2004-12-20 CN CN200480041764XA patent/CN1918284B/zh not_active Expired - Lifetime
- 2004-12-20 EA EA200601187A patent/EA200601187A1/ru unknown
- 2004-12-20 CA CA2549930A patent/CA2549930C/en not_active Expired - Fee Related
- 2004-12-20 BR BRPI0417194-2A patent/BRPI0417194A/pt active Search and Examination
-
2009
- 2009-03-03 US US12/397,246 patent/US20090170193A1/en not_active Abandoned
-
2012
- 2012-08-24 JP JP2012185019A patent/JP2013039128A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA2549930A1 (en) | 2005-06-30 |
| EA200601187A1 (ru) | 2006-12-29 |
| KR20070004574A (ko) | 2007-01-09 |
| US20070274970A1 (en) | 2007-11-29 |
| EP1697500A1 (en) | 2006-09-06 |
| WO2005059113A1 (en) | 2005-06-30 |
| JP2013039128A (ja) | 2013-02-28 |
| US20090170193A1 (en) | 2009-07-02 |
| MXPA06006706A (es) | 2007-01-19 |
| EP1697500B1 (en) | 2013-03-20 |
| CN1918284B (zh) | 2012-07-04 |
| JP2007514434A (ja) | 2007-06-07 |
| CA2549930C (en) | 2014-02-11 |
| GB0329449D0 (en) | 2004-01-28 |
| BRPI0417194A (pt) | 2007-03-06 |
| CN1918284A (zh) | 2007-02-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2549930C (en) | Cd34+ stem cells | |
| US7625752B2 (en) | Cellular compositions and methods of making and using them | |
| EP2956538B1 (en) | Bioengineered liver constructs and methods relating thereto | |
| KR101119878B1 (ko) | 프리미티브 간 줄기세포 및 프록시멀 간 줄기세포 | |
| US20080118477A1 (en) | Umbilical cord mesenchymal stem cells support cord blood hematopoiesis | |
| US20130266543A1 (en) | Multipotent Adult Stem Cell Population | |
| WO2010039241A1 (en) | Methods for isolating very small embryonic-like (vsel) stem cells | |
| EP3395943B1 (en) | Method for manufacturing tissue/organ by using blood cells | |
| WO2012133948A1 (ja) | 生体組織から単離できるssea-3陽性の多能性幹細胞を含む他家移植用細胞治療用組成物 | |
| Abe et al. | Lung cells transplanted to irradiated recipients generate lymphohematopoietic progeny | |
| KR100773253B1 (ko) | 성체줄기세포와의 공동배양을 통한 조혈모세포의 배양 및증식방법 | |
| Fang et al. | Hemangioblastic characteristics of human adipose tissue-derived adult stem cells in vivo | |
| WO2026013575A1 (en) | Modeling developmental hematopoietic niches of human embryo for near-physiological blood stem cell expansion ex vivo | |
| Kelley et al. | Collection and Expansion of Stem Cells | |
| Zedan | Transplantation of Mesenchymal Stem Cells into Experimental Injured Mice Liver |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |